Agenus’ (AGEN) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright restated their neutral rating on shares of Agenus (NASDAQ:AGEN) in a research note published on Tuesday morning,Benzinga reports.

Separately, Robert W. Baird decreased their price target on Agenus from $6.00 to $3.00 and set a “neutral” rating for the company in a research note on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8.75.

Agenus Stock Performance

Shares of NASDAQ AGEN opened at $1.73 on Tuesday. The stock has a fifty day moving average price of $3.10 and a two-hundred day moving average price of $3.73. The firm has a market cap of $40.58 million, a P/E ratio of -0.15 and a beta of 1.23. Agenus has a 1 year low of $1.64 and a 1 year high of $19.69.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.36) by $0.32. The firm had revenue of $26.84 million for the quarter, compared to the consensus estimate of $30.09 million. On average, research analysts predict that Agenus will post -12.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agenus

Several large investors have recently modified their holdings of AGEN. FMR LLC boosted its stake in shares of Agenus by 47.1% during the 3rd quarter. FMR LLC now owns 85,301 shares of the biotechnology company’s stock worth $467,000 after acquiring an additional 27,309 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Agenus by 2,271.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company’s stock worth $217,000 after acquiring an additional 37,866 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Agenus during the 3rd quarter worth $1,003,000. HighTower Advisors LLC boosted its stake in shares of Agenus by 46.1% during the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 7,530 shares in the last quarter. Finally, Point72 DIFC Ltd boosted its stake in shares of Agenus by 380.0% during the 3rd quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 11,542 shares in the last quarter. 61.46% of the stock is owned by institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.